Introduction {#tca13456-sec-0008}
============

Malignant pleural mesothelioma (MPM) is a rare tumour[1](#tca13456-bib-0001){ref-type="ref"} strongly associated with asbestos exposure. In Europe, the MPM incidence rates (IR) are expected to peak around 2020 in some countries, but a decrease may have already begun in others[2](#tca13456-bib-0002){ref-type="ref"}, [3](#tca13456-bib-0003){ref-type="ref"} as a consequence of legislative restrictions implemented in the 1980s. In Italy, a downturn in the occurrence of MPM is expected to occur after 2019.[4](#tca13456-bib-0004){ref-type="ref"} However, 1450 new MPM (IR 3.3 and 0.9 in males and females, respectively) patients were diagnosed in 2014 and the IR across Italian geographical areas ranged from \<4/100 000 to \>100/100 000.[5](#tca13456-bib-0005){ref-type="ref"}

MPM has a poor prognosis (five‐year survival 9%)[6](#tca13456-bib-0006){ref-type="ref"} and no survival progresses have been observed at population level during the last decades.[6](#tca13456-bib-0006){ref-type="ref"} Traditionally, the centralization of rare cancer in dedicated centers has been recommended to ensure expertise, multidisciplinarity and access to innovation.[7](#tca13456-bib-0007){ref-type="ref"} Nevertheless, this process requires health migration, rationing of resources and a potential failure in routine care since the limited expert resources may be overwhelmed, determining waiting lists.[7](#tca13456-bib-0007){ref-type="ref"} By ensuring appropriate care of all patients regardless of the point of access, networking seems to be the most appropriate answer to rare cancers such as MPM.[7](#tca13456-bib-0007){ref-type="ref"} In Italy, specialized centers for MPM patients have not been identified in all regions and, up to 2017, only an informal professional network on rare cancers, focused mainly on sarcoma tumors, was created to provide second opinion and clinical advice on rare cancers.[8](#tca13456-bib-0008){ref-type="ref"}

Against this background, we aimed to: (i) Describe the treatment patterns among MPM patients in Italy and across Italian regions; and (ii) identify patients and health care system factors associated with treatment patterns across Italian regions.

Methods {#tca13456-sec-0009}
=======

This population‐based study is part of the wider "MPM survivors in Italy: what is contributing to long term survival?" (LUME) project. The LUME project collaborated with 26 population‐based registries to develop a national, population‐based database of MPM patients with demographic and clinical information. Regional registries (centri operativi regionali‐COR) from the National mesothelioma‐dedicated surveillance system and general cancer registries (CRs) contributed to the LUME database. General CRs were used when a COR either was not available in a region, or did not accept a request to join the study. The 26 registries involved covered 70% of the Italian population (Fig [1](#tca13456-fig-0001){ref-type="fig"}) and registered 80% of all MPM cases in Italy. Veneto COR contributed with the Padua province data only; however, we will refer to it as Veneto region; Trento CR will be referred to as Trentino Alto Adige region; Siracusa, Trapani, Palermo, Catania‐Messina and Ragusa CRs will be referred to as Sicily region and Parma, Reggio Emilia, Modena and Romagna CRs as Emilia‐Romagna region (Fig [1](#tca13456-fig-0001){ref-type="fig"}).

![Italian geographical areas (regions) included in the study.](TCA-11-1661-g001){#tca13456-fig-0001}

About 5600 MPM, histologically or cytologically confirmed, were identified from 2003 to 2008 by the registries involved in the LUME project. Patients diagnosed from death certificate or autopsy were excluded. Clinical information are not routinely collected by these registries thus an ad hoc data collection was organized to retrieve them including diagnostic procedures, histology, clinical and pathological stage, treatment information (surgery \[SRG\], radiotherapy \[RT\], chemotherapy \[CHT\] and best supportive care \[BSC\]), hospital of origin (including information on the availability of an onsite thoracic surgical department), and follow‐up. Data collection was based on a common protocol, agreed by a multidisciplinary group including registrars, epidemiologist and MPM clinical experts (pathologists, surgeons and oncologists).

Due to restricted financial resources the LUME project could not collect data for all the 5600 cases but for a representative random sample of 2026 MPM patients, taking into consideration the relative numerical contribution of each registry.

Clinical and pathological T, N and M were those defined by the clinicians. The TNM Staging System proposed from the International Mesothelioma Interest Group was used for the analyses.[9](#tca13456-bib-0009){ref-type="ref"}

We defined the first course of treatment as the one started within five months from the diagnosis:Surgery alone (including extra pleural pneumonectomy \[EPP\], pleurectomy with decortications \[P/D\] and pleurectomy);Chemotherapy alone;Chemotherapy and surgery (SRG + CHT);Multimodal approach consisting of EPP + radical RT + CHT;Other treatment combinations (including SRG + radical RT; CHT + radical RT; surgery≠EPP + radical RT + CHT);No treatment (including also BSC);Missing information.

For the treatment time frame please refer to Supplementary material B, Table [S1](#tca13456-supitem-0001){ref-type="supplementary-material"}.

###### 

Demographic and clinical characteristics of malignant pleural mesothelioma patients diagnosed 2003--2008 in the LUME study

  Variable                                                                                Category                        No. of cases   \%
  --------------------------------------------------------------------------------------- ------------------------------- -------------- ------
  Total                                                                                                                   2026           100
  Age class                                                                               15--54                          188            9.3
  55--64                                                                                  475                             23.4           
  65--74                                                                                  733                             36.2           
  75+                                                                                     630                             31.1           
  Sex                                                                                     Male                            1438           71
  Female                                                                                  588                             29             
  Histotype                                                                               Epitheliod                      1384           68.3
  Not otherwise specified                                                                 236                             11.7           
  Biphasic                                                                                229                             11.3           
  Sarcomatoid                                                                             177                             8.7            
  Diagnostic confirmation                                                                 Histological                    1917           94.6
  Cytological                                                                             109                             5.4            
  Imaging                                                                                 CT scan or/and PET or/and MRI   1818           89.7
  X‐ray alone                                                                             164                             8.1            
  None                                                                                    44                              2.2            
  Clinical stage[**†**](#tca13456-note-0001){ref-type="fn"}                               Stage I--II                     928            45.8
  Stage III                                                                               375                             18.5           
  Stage IV                                                                                426                             21.0           
  Missing information                                                                     297                             14.7           
  First course of treatment                                                               Surgery alone                   135            6.7
  Surgery and chemotherapy                                                                206                             10.2           
  Chemotherapy alone                                                                      833                             41.1           
  Multimodal treatment                                                                    17                              0.8            
  Other combination of treatments                                                         21                              1              
  No treatment or best supportive care                                                    739                             36.5           
  Missing information                                                                     75                              3.7            
  Information on the type of surgery (over 341 surgery ± chemotherapy treated patients)   Extra pleural pneumonectomy     134            39.3
  Pleurectomy with decortication (P/D)                                                    101                             29.6           
  Pleurectomy                                                                             82                              24.1           
  Information on type of surgery missing                                                  24                              7              

AJCC.[9](#tca13456-bib-0009){ref-type="ref"}

We used standard age groups: 15--54; 55--64; 65--74 and 75+.[10](#tca13456-bib-0010){ref-type="ref"}

To identify factors associated with patterns of treatment across the different Italian geographical areas, we fitted a multinomial logistic regression model, considering as the dependent variable the most common treatment options (CHT or SRG alone, SRG + CHT, no active treatment) with "CHT alone" acting as reference. We included as the independent variables patients/tumors characteristics available in the LUME database (age, sex, stage and histology), Italian regions and health care system factors possibly associated with receipt of MPM treatment (ie, availability of a thoracic surgery department in the hospitals). For the independent variables, the category with highest frequency was the reference (ref). The output of this model is the relative risk ratio (RRR) of those who received a specific treatment versus "CHT alone". Two‐sided *P*‐values\<0.05 were considered significant.

All statistical analyses were performed using Stata, release 13.0 (Stata Corporation, College Station, TX, USA).

Results {#tca13456-sec-0010}
=======

Clinical and demographic patient\'s characteristics are summarized in Table [1](#tca13456-tbl-0001){ref-type="table"}. Of 2026 MPM patients, 67% were diagnosed with cancer at 65 years or more (average age: 69 years), 71% were males and 68% with epitheliod histotype. Around half of patients (46%) were diagnosed with stage I--II of disease and 41% were treated with CHT alone. EPP, P/D and pleurectomy were used in 40%, 30% and 24% of the MPM surgically treated, respectively.

A description of the first course of treatment by stage and age groups is reported in Table [2](#tca13456-tbl-0002){ref-type="table"}. Regardless stage, CHT was the most common treatment option at all ages, apart from elderly patients (75+ years) who received less active treatments and more BSC compare to younger patients. MPM patients with stage I--II and III were more likely to be treated with SRG as compared to those diagnosed with stage IV. The type of SRG (EPP, P/D or pleurectomy) did not differ much across the stages. Younger patients (\<65 years) were most likely to receive the EPP. SRG+/‐CHT use decreased with increasing age. Combined and multimodal approaches were used more for younger patients (\<65 years).

###### 

First course of treatment for malignant pleural mesothelioma patients included in the study by stage and by age and stage

  ------------------ ------ ------ ------ ------ ----- ----- ------ ------
  Stage I--II         928   8.8    39     13.3   1.3   0.7   33.6   3.3
  Stage III           375   6.8    50.1   7.2    0.5   0.5   31.7   3.2
  Stage IV            426   3.8    47.2   8.5    0.2   2.8   35.5   2
  Missing             297   3.7    29     6.4    0.7   0.7   52.2   7.3
  Overall             2026  6.6    41.3   10.1   0.8   1.1   36.4   3.7
  15--54 years old                                                  
  Stage I--II          79   13.9   38.0   30.4   2.5   0.0   10.1   5.1
  Stage III            47   6.4    51.1   6.4    2.1   2.1   27.7   4.2
  Stage IV             42   11.9   52.4   14.3   0.0   2.4   14.3   4.7
  Missing              20   15.0   40.0   15.0   0.0   0.0   20.0   10.0
  Overall             188   11.7   44.7   19.1   1.6   1.1   16.5   5.3
  55--64 years old                                                  
  Stage I--II         215   10.7   44.7   21.9   2.3   1.4   17.7   1.3
  Stage III            88   9.1    48.9   18.2   1.1   0.0   17.1   5.6
  Stage IV            109   3.7    51.4   16.5   0.0   4.6   22.0   1.8
  Missing              63   4.8    42.9   11.1   0.0   0.0   31.8   9.4
  Overall             475   8.0    46.7   18.5   1.3   1.7   20.4   3.4
  65--74 years old                                                  
  Stage I--II         337   8.9    47.8   12.5   1.5   0.6   24.9   3.8
  Stage III           141   5.7    63.1   5.7    0.0   0.0   24.1   1.4
  Stage IV            161   3.1    59.6   6.2    0.6   2.5   26.1   1.9
  Missing              94   2.2    37.2   9.6    2.1   2.1   40.4   6.4
  Overall             733   6.1    52.0   9.4    1.1   1.1   27.0   3.3
  75+ years old                                                     
  Stage I--II         297   6.1    25.3   3.4    0.0   0.3   61.3   3.6
  Stage III            99   6.1    32.3   0.0    0.0   1.0   57.6   3.0
  Stage IV            114   1.8    23.7   1.8    0.0   1.7   69.3   1.7
  Missing             120   2.5    13.3   0.0    0.0   0.0   77.5   6.7
  Overall             630   4.6    23.8   1.9    0.0   0.6   65.3   3.8
  ------------------ ------ ------ ------ ------ ----- ----- ------ ------

Best supportive care.

In all regions most of MPM patients were males and with epitheliod histotype (Supplementary material B, Table [S2](#tca13456-supitem-0002){ref-type="supplementary-material"}). MPM patients\' age distribution by geographical areas in our sample corresponded to the age distribution in the general population,[11](#tca13456-bib-0011){ref-type="ref"} older patients were diagnosed in the center and north west of Italy (eg, Tuscany, Liguria, Marche, Umbria) whereas in southern Italy (eg, Campania, Sicily) the patients were younger (Supplementary material B, Table [S2](#tca13456-supitem-0002){ref-type="supplementary-material"}). Patients were mainly diagnosed with stage I--II across regions with differences ranging from about 30% in Sicily and Trentino Alto Adige to 57% in Lombardy (Table [3](#tca13456-tbl-0003){ref-type="table"}a). Whereas patients with stage III and IV were diagnosed mostly in Trentino Alto Adige, Veneto, Umbria and Emilia‐Romagna (Table [3](#tca13456-tbl-0003){ref-type="table"}a). Compared to the other regions, in Tuscany and Sicily patients were more likely to be treated with SRG+/‐CHT (34% and 27%, respectively) whereas in Liguria and Piedmont patients were less likely to be treated (no treatment in 50% and 46%, respectively) (Table [3](#tca13456-tbl-0003){ref-type="table"}b). CHT use varied across geographical areas ranging from about 71% in Trentino Alto Adige to 28% in Campania (Table 3b). EPP was the most used type of surgery in all regions except for Campania, Tuscany, Umbria and Piedmont (data available from the corresponding author).

###### 

Distribution of clinical stage (**a**) and the first course of treatment (**b**) of malignant pleural mesothelioma patients included in the study, by Italian geographical areas

  --------------------- ----- ---- ---- ---- --
  Lombardy              455   57   41   2    
  Piedmont              371   50   32   18   
  Tuscany               192   48   26   26   
  Umbria                39    46   51   3    
  Liguria               200   44   34   22   
  Marche                75    44   47   9    
  Emilia‐Romagna        118   42   50   9    
  Veneto                37    41   51   8    
  Lazio                 156   39   49   12   
  Campania              207   39   44   17   
  Trentino‐Alto Adige   7     29   71   0    
  Sicily                169   27   43   30   
  --------------------- ----- ---- ---- ---- --

  --------------------- ----- ---- ---- ---- ----
  Trentino‐Alto Adige   7     71   14   14   0
  Marche                75    59   17   20   0
  Lazio                 156   51   10   40   0
  Veneto                37    49   16   22   11
  Sicily                169   47   27   21   4
  Lombardy              455   45   17   34   0
  Umbria                39    44   10   41   0
  Emilia‐Romagna        118   43   16   36   2
  Piedmont              371   40   12   46   0
  Liguria               200   36   13   50   1
  Tuscany               192   32   34   30   4
  Campania              207   28   11   35   25
  --------------------- ----- ---- ---- ---- ----

The ranking of the Italian geographical areas is the % of stage I--II in Table [3](#tca13456-tbl-0003){ref-type="table"}a and the % of chemotherapy alone in Table [3](#tca13456-tbl-0003){ref-type="table"}b.

The sum of each row, Italian geographical areas, does not add up at 100% due to the lack of inclusion of multimodal and other combination of treatments that occurred in few cases across the regions.

The model results (Table [4](#tca13456-tbl-0004){ref-type="table"}) confirmed that SRG (RRR = 2.35) use was more common than CHT in young MPM patients (15--54 years) compared to 65--74 years old. In addition, old MPM patients (RRR = 5.32), those with missing information on stage (RRR = 2.33), females (RRR = 1.47) and those with not specified and sarcomatoid histotype (RRR = 1.7 and RRR = 1.8) were more likely to get BSC than CHT (Table [4](#tca13456-tbl-0004){ref-type="table"}). Use of SRG+/‐CHT was more common than CHT alone in MPM patients with stage I--II compared to all other stages. Finally, the availability of a thoracic surgery onsite increased the likelihood to receive SRG + CHT (RRR = 2.23).

###### 

Age‐, stage‐, sex‐, histology‐, hospital with thoracic surgical department‐adjusted relative risk ratios (RRR) of first course of treatment in relation to Italian geographical areas and their corresponding 95% confidence interval (95% CI)

                                                                                            First course of treatment RRR[†](#tca13456-note-0007){ref-type="fn"} (95% CI)                                                               
  ----------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------- -------------------
  Age group                     65--74                                                      1 (ref)                                                                         1 (ref)                                                     1 (ref)
  15--54                        2.35[\*](#tca13456-note-0006){ref-type="fn"} (1.32--4.2)    2.63[\*](#tca13456-note-0006){ref-type="fn"} (1.6--4.34)                        0.67 (0.42--1.07)                                           
  55--64                        1.49 (0.93--2.39)                                           2.35[\*](#tca13456-note-0006){ref-type="fn"} (1.62--3.43)                       0.81 (0.6--1.11)                                            
  75+                           1.66 (0.99--2.78)                                           0.41[\*](#tca13456-note-0006){ref-type="fn"} (0.21--0.79)                       5.32[\*](#tca13456-note-0006){ref-type="fn"} (4.06--6.98)   
  Stage                         Stage I--II                                                 1 (ref)                                                                         1 (ref)                                                     1 (ref)
  Stage III                     0.61[\*](#tca13456-note-0006){ref-type="fn"} (0.37--0.99)   0.48[\*](#tca13456-note-0006){ref-type="fn"} (0.29--0.77)                       0.77 (0.57--1.05)                                           
  Stage IV                      0.36[\*](#tca13456-note-0006){ref-type="fn"} (0.20--0.64)   0.44[\*](#tca13456-note-0006){ref-type="fn"} (0.28--0.68)                       1.05 (0.79--1.41)                                           
  Missing                       0.48[\*](#tca13456-note-0006){ref-type="fn"} (0.24--0.97)   0.46[\*](#tca13456-note-0006){ref-type="fn"} (0.26--0.83)                       2.33[\*](#tca13456-note-0006){ref-type="fn"} (1.63--3.32)   
  Sex                           Male                                                        1 (ref)                                                                         1 (ref)                                                     1 (ref)
  Female                        1.01 (0.66--1.55)                                           0.75 (0.5--1.12)                                                                1.47[\*](#tca13456-note-0006){ref-type="fn"} (1.15--1.89)   
  Histology                     Epitheliod                                                  1 (ref)                                                                         1 (ref)                                                     1 (ref)
  NOS or not available          0.6 (0.26--1.36)                                            0.89 (0.48--1.65)                                                               1.7[\*](#tca13456-note-0006){ref-type="fn"} (1.19--2.44)    
  Biphasic                      1.35 (0.77--2.37)                                           1.74[\*](#tca13456-note-0006){ref-type="fn"} (1.09--2.78)                       1.11 (0.77--1.61)                                           
  Sarcomatoid                   1.12 (0.55--2.31)                                           1.11 (0.59--2.1)                                                                1.8[\*](#tca13456-note-0006){ref-type="fn"} (1.21--2.67)    
  Region                        Lombardy                                                    1 (ref)                                                                         1 (ref)                                                     1 (ref)
  Trentino‐Alto Adige           n.a                                                         1.69 (0.16--17.41)                                                              0.27 (0.02--3.06)                                           
  Veneto                        0.35 (0.04--2.72)                                           1.29 (0.43--3.87)                                                               0.65 (0.26--1.65)                                           
  Piedmont                      0.71 (0.38--1.3)                                            0.67 (0.38--1.17)                                                               1.73[\*](#tca13456-note-0006){ref-type="fn"} (1.23--2.45)   
  Liguria                       1.48 (0.77--2.87)                                           0.55 (0.24--1.25)                                                               1.87[\*](#tca13456-note-0006){ref-type="fn"} (1.23--2.85)   
  Tuscany                       1.91 (0.99--3.67)                                           3.98[\*](#tca13456-note-0006){ref-type="fn"} (2.31--6.85)                       0.81 (0.50--1.31)                                           
  Emilia‐Romagna                0.64 (0.23--1.72)                                           1.42 (0.71--2.87)                                                               1.16 (0.70--1.93)                                           
  Marche                        0.32 (0.07--1.39)                                           1.53 (0.70--3.35)                                                               0.3[\*](#tca13456-note-0006){ref-type="fn"} (0.15--0.59)    
  Umbria                        0.78 (0.17--3.68)                                           0.75 (0.16--3.61)                                                               1.23 (0.55--2.74)                                           
  Lazio                         0.68 (0.30--1.50)                                           0.35[\*](#tca13456-note-0006){ref-type="fn"} (0.14--0.87)                       1.38 (0.88--2.15)                                           
  Campania                      1.19 (0.56--2.53)                                           0.73 (0.34--1.55)                                                               2.66[\*](#tca13456-note-0006){ref-type="fn"} (1.68--4.22)   
  Sicily                        1.14 (0.55--2.36)                                           2.19[\*](#tca13456-note-0006){ref-type="fn"} (1.24--3.87)                       0.44[\*](#tca13456-note-0006){ref-type="fn"} (0.26--0.75)   
  Thoracic surgery department   Yes                                                         1.58 (0.98--2.56)                                                               2.23[\*](#tca13456-note-0006){ref-type="fn"} (1.43--3.5)    0.81 (0.63--1.04)

NOS, not otherwise specified, n.a., not applicable; ref, reference.

Statistically significant.

RRRs calculated by multinomial logistic regression modeling taking "chemotherapy alone" as reference.

The model results showed that considering system level characteristics (ie, availability of a thoracic surgical department) did not fully explain the differences on first course of treatment observed across the Italian regions. Thus, compared to MPM patients living in Lombardy and getting CHT alone, after adjusting for age, sex, histology, stage and thoracic surgery onsite MPM patients living in:Piedmont, Liguria and Campania had a higher RRR to be untreated,Tuscany and Sicily had a higher RRR to get treatment including SRG,Marche and Sicily had a lower RRR to be untreated and,Lazio had a lower RRR to get SRG + CHT (than so more likely to receive CHT alone).

No major differences were confirmed across the other geographical areas.

Discussion {#tca13456-sec-0011}
==========

This is the first population‐based study to provide a description of the treatment patterns up to 2008 for MPM patients in Italy and across different Italian geographical areas. It is the results of a unique collaborative effort including 26 registries from 12 of 21 Italian regions corresponding to 70% of the Italian population. Previous Italian studies analyzed survival of MPM patients with limited information on treatment[10](#tca13456-bib-0010){ref-type="ref"}, [12](#tca13456-bib-0012){ref-type="ref"} and generally were focused on one region.[13](#tca13456-bib-0013){ref-type="ref"}, [14](#tca13456-bib-0014){ref-type="ref"}

In our study, 36% MPM patients did not receive active cancer treatment, especially elderly patients (65%) independently of disease stage. However, in our database we had not got the information to distinguish MPM patients unsuitable for systemic therapy from those untreated because they were most likely under observation. Our results are similar to those reported in 2011 in the USA, and 29% of MPM who did not receive active cancer treatment were principally older patients.[15](#tca13456-bib-0015){ref-type="ref"}

Therapeutic decisions in the elderly with cancer should not be based just on chronological age but should also take into account the patient preferences, functional age, presence of comorbidities and estimated benefits and risks.[16](#tca13456-bib-0016){ref-type="ref"}, [17](#tca13456-bib-0017){ref-type="ref"}

In our study, 41% received chemotherapy alone. MPM patients were also reported to be mainly treated with CHT in Belgium (60%), Netherlands (41%) and England (37%).[18](#tca13456-bib-0018){ref-type="ref"} In Slovenia, the number of patients treated with CHT increased from 32% in 1999--2003 to 80% in 2004--2008 due to the systematic introduction of CHT.[19](#tca13456-bib-0019){ref-type="ref"} Also, in the USA in 2011, MPM patients receiving systemic therapy were 60%.[15](#tca13456-bib-0015){ref-type="ref"}

In our study, 19% received a treatment including SRG. In Europe, surgery was used in 27%, 10% and 5% MPM patients in Belgium, England and Netherlands, respectively (years of diagnosis 2006--2011).[18](#tca13456-bib-0018){ref-type="ref"} In Slovenia, the number of patients treated by surgery decreased from 21% in 1999--2003 to 7% in 2004--2008.[19](#tca13456-bib-0019){ref-type="ref"} In the USA, cancer‐directed surgery was reported in 22%, 23% and 27% in MPM patients in the years 1990--2004,[20](#tca13456-bib-0020){ref-type="ref"} 1973--2009[21](#tca13456-bib-0021){ref-type="ref"} and 2011,[15](#tca13456-bib-0015){ref-type="ref"} respectively.

The available data showed a heterogeneity of treatment across geographical areas and time periods. However, CHT was confirmed as the main treatment option for MPM patients in most EU countries and USA while the multimodal approach had a limited use worldwide. These reports pre‐date the results of the MARS study[22](#tca13456-bib-0022){ref-type="ref"} and enhance the support that patients who are candidates for a multimodal approach should be included in clinical trials at highly specialized centers. In the last decade, no developments have been observed regarding systemic treatment. Cisplatin and pemetrexed have remained the standard of care in MPM patients for around 20 years. Recently, various studies have explored the role of immunotherapy and its combination with standard CHT in advanced MPM patients and preliminary results seems to predict a better survival rate compared to CHT alone. Nevertheless, it appears that CHT is the best treatment option.[23](#tca13456-bib-0023){ref-type="ref"}, [24](#tca13456-bib-0024){ref-type="ref"}, [25](#tca13456-bib-0025){ref-type="ref"}

Our results showed that the majority of patients are diagnosed with stage I--II and 21% with stage IV. In the USA, two studies[20](#tca13456-bib-0020){ref-type="ref"}, [21](#tca13456-bib-0021){ref-type="ref"} reported that only 11% MPM patients are diagnosed with early disease and patients diagnosed with distant disease range from 16%[20](#tca13456-bib-0020){ref-type="ref"} to 59%.[21](#tca13456-bib-0021){ref-type="ref"} Stage definition and study period could explain the differences in stage distribution across these studies. Another study in the USA[26](#tca13456-bib-0026){ref-type="ref"} reported 28% were stage I and II; 14% stage III, 29% stage IV with 29% of stage information missing from 2005 to 2009. In our study, missing information was around 15%; 90% of cases were staged based on CT scan/RMI/PET. In any case, we cannot rule out a possible stage misclassification also in our data considering the interpersonal variability of the radiologists.[27](#tca13456-bib-0027){ref-type="ref"}

In our study, we found that the first course of treatment for MPM patients differed across geographical areas. The observed differences could be due to the different availability of a thoracic surgery department but, as showed by the proposed model, these factors did not fully explain the observed differences on treatment approach across regions. We believe that these differences may be due to the limited expertise available for a rare cancer such as MPM and also to the lack of a network able to maximize the available expertise.

In Italy, three consensus conferences on the management of MPM took place in 2011, 2013 and 2015[25](#tca13456-bib-0025){ref-type="ref"}, [28](#tca13456-bib-0028){ref-type="ref"}, [29](#tca13456-bib-0029){ref-type="ref"} to develop recommendations on MPM management for public health institutions, clinicians and patients. From the health care organization, some regions (eg, Emilia‐Romagna) have identified a clinical network for the management of MPM patients. More importantly, the Italian rare cancers network was established by a formal agreement between the Ministry of Health and the different Italian Regions ("Intesa Stato‐Regioni") in September 2017.

The time of our analyses (patients diagnosed in 2003--2008) pre‐dates implementation of regional and national initiatives to ameliorate the quality of care for MPM patients and thus provides important baseline data to evaluate such initiatives. Limitations of our study include the lack of information on comorbidity and performance status, which is relevant for interpreting the treatment choice. Strengths are the centralization of data quality checks and analyses along with the population‐based nature of this effort.

In the future, population‐based data will be crucial to assess whether changes in management policies have the desired effect to ensure the best care for all MPM patients.

Disclosure {#tca13456-sec-0013}
==========

All authors declare no competing interests.

Supporting information
======================

###### 

**Appendix S1.** LUME Study Working Group.

###### 

Click here for additional data file.

###### 

**Table S1.** Definition of first course of treatment collected in the LUME study.

**Table S2.** Demographic characteristics and histotype of malignant pleural mesothelioma patients included in the LUME study by Italian geographical areas.
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